Plain-English translation of NCT06451588 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing fecal microbiota transplantation () — a treatment that transfers healthy gut bacteria from a donor into your body — to see if it can help people with axial spondyloarthritis whose disease is still active despite taking anti-inflammatory medications. Research shows that people with this spinal condition often have an imbalance in their gut bacteria, which may be connected to disease activity. This study will compare from healthy donors against a placebo treatment (using your own bacteria) to see if the healthy donor bacteria can reduce inflammation and improve your symptoms.
Many patients with axial spondyloarthritis continue to have active disease even after taking strong anti-inflammatory drugs, and doctors need new treatment options. Growing evidence suggests that an imbalance in gut bacteria may play a role in this condition, making a promising approach worth testing.
You likely qualify if…
You likely don't qualify if…
If you're accepted into this study, you will receive a single treatment at the beginning: a liquid enema containing either healthy donor bacteria or your own bacteria (depending on which group you're randomly assigned to). You'll be part of a double-blind study, meaning neither you nor the researchers will know which treatment you received. The study will follow you over time with clinic visits and tests to measure your disease activity, inflammation levels, and symptom improvement. You'll need to avoid antibiotics and maintain stable doses of your current medications during the study period.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Norway